Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.

Expert review of clinical pharmacology - 1 Nov 2016

El Kassas Mohamed, Elbaz Tamer, Abd El Latif Yasmeen, Esmat Gamal

Abstract excerpt

INTRODUCTION: During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of direct antiviral agents especially for patients with HCV genotypes 1 and 4 infections. Elbasvir (NS5A inhibitor) and grazoprevir (NS3/4A protease inhibitor) are newly developed drugs that are presented in fixed dose combination tablets. Areas covered: This review covers the mechanism of action,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Benzofurans
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Imidazoles

Share to Quinoxalines

Source

Identifiers

PMID: 27603877
DOI: 10.1080/17512433.2016.1233813

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.PMID 27603877Read ↗

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Semantic proximity Read ↗

Preclinical and clinical properties of elbasvir (ERELSA® Tablets 50 mg) and Grazoprevir (GRAZYNA® Tablets 50 mg), novel therapeutic agents for hepatitis C.Semantic proximity Read ↗

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.Semantic proximity Read ↗

[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic].Semantic proximity Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.Semantic proximity Read ↗

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.Semantic proximity Read ↗

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.Semantic proximity Read ↗

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.Semantic proximity Read ↗

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.Semantic proximity Read ↗

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.Semantic proximity Read ↗

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.